In recent years, anti-cancer immunotherapy plays a vital role in treating advanced cancers, showing a promising outcome in clinical practice. For example, Immune Checkpoint Inhibitors activate T cells and promote anti-tumor immunity. Indeed, the interaction between T cells, cancer cells, and other immune cells such as cancer-associated fibroblast (CAF) could determine the direction of the immune response. In the last decades, investigators found epigenetic change including DNA and RNA modification regulates gene expression and affects many processes in tumor biology. And the epigenetic marks like m6a RNA methylation were found to be involved in T cell infiltration and activation. However, the molecular mechanisms by which the epigenetic marks regulate anti-tumor responses and influence the effect of immunotherapy are largely unknown. Thus, we proposed a research topic on the interaction between epigenetic marks and anti-tumor immunity, which we believe will provide important and novel insight into cancer immunity.
This Research Topic is centered around all aspects of the epigenetic regulation in cancer immunity. We aim to discover mechanisms of epigenetic regulation in cancer immunity, biomarkers of the prognostic or anti-tumor immune responses, and possible epigenetic targeting immune therapeutics. We hope this Research Topic will enrich our understanding of cancer immunity.
Areas of interest include but are not limited to the following aspects:
• Mechanisms on non-coding RNA regulation of cancer immunity
• Non-coding RNA and tumor immune microenvironment
• Key epigenetic biomarkers for immunotherapy prediction
• Epigenetic drugs in cancer immunotherapy
• Epigenetic mechanisms of immune escape in cancer
In recent years, anti-cancer immunotherapy plays a vital role in treating advanced cancers, showing a promising outcome in clinical practice. For example, Immune Checkpoint Inhibitors activate T cells and promote anti-tumor immunity. Indeed, the interaction between T cells, cancer cells, and other immune cells such as cancer-associated fibroblast (CAF) could determine the direction of the immune response. In the last decades, investigators found epigenetic change including DNA and RNA modification regulates gene expression and affects many processes in tumor biology. And the epigenetic marks like m6a RNA methylation were found to be involved in T cell infiltration and activation. However, the molecular mechanisms by which the epigenetic marks regulate anti-tumor responses and influence the effect of immunotherapy are largely unknown. Thus, we proposed a research topic on the interaction between epigenetic marks and anti-tumor immunity, which we believe will provide important and novel insight into cancer immunity.
This Research Topic is centered around all aspects of the epigenetic regulation in cancer immunity. We aim to discover mechanisms of epigenetic regulation in cancer immunity, biomarkers of the prognostic or anti-tumor immune responses, and possible epigenetic targeting immune therapeutics. We hope this Research Topic will enrich our understanding of cancer immunity.
Areas of interest include but are not limited to the following aspects:
• Mechanisms on non-coding RNA regulation of cancer immunity
• Non-coding RNA and tumor immune microenvironment
• Key epigenetic biomarkers for immunotherapy prediction
• Epigenetic drugs in cancer immunotherapy
• Epigenetic mechanisms of immune escape in cancer